Designing for Scale: Building Commercial Readiness Into CGT Manufacturing From Day One

April 1, 2026 - 07:34

The journey from a promising clinical result to reliable, commercial-scale manufacturing remains a formidable hurdle for cell and gene therapy (CGT) developers. Industry experts now emphasize that the key to overcoming this challenge lies in integrating commercial readiness into process design from the very first stages of development.

A reactive approach, where processes are optimized for the lab and later re-engineered for larger scale, often leads to costly rework, delays, and significant risk. The emerging strategy focuses on forward-thinking design. By implementing advanced process controls and real-time analytics early, developers can create robust, standardized processes that are inherently scalable.

This proactive methodology ensures that critical quality attributes are consistently met, even as production volumes increase. It reduces the need for major process changes after clinical trials, smoothing the transition to commercial manufacturing. Ultimately, building with scale in mind from day one is not just an engineering best practice; it is a crucial business strategy for bringing transformative therapies to patients faster and more reliably.